Zanubrutinib, the most recently approved BTK inhibitor, has not yet been evaluated for repurposing for solid tumours, although its biochemical and pharmacokinetic properties suggest possible activity towards HER2-overexpressing cancers. This evidence concerns the gene ERBB2 and cancer.